{"filings":[{"id":584036,"accession_number":"0001628280-26-037377","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2026-05-21T21:04:36+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicara reports 31% 3-year OS with ficerafusp alfa + pembro in 1L R/M HPV-negative HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ficerafusp alfa 1500mg QW + pembrolizumab showed estimated 31% OS at 3 years, ~double retrospective standard of care OS (Vasiliadou et al. 2024).","CR rates matured to 13%, 25%, 30% across 750mg QW, 1500mg QW, 2000mg Q2W cohorts; deep responses (≥80% shrinkage) in 80% and 77% at higher doses.","Pooled analysis: deep responders had median DOR 31.6 months, median PFS 36.9 months (65% risk reduction), median OS not reached (63% risk reduction).","Company plans to initiate a loading-dose regimen study (2250mg Q3W) in Q3 2026 to support long-term administration.","Phase 3 FORTIFI-HN01 pivotal study ongoing; data presented at ASCO 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97265,"accession_number":"0001628280-26-033135","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicara Q1 net loss $56.2M; cash $539.8M; appoints new CMO and CCO; advances ficerafusp alfa","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $56.2M for Q1 2026 vs $36.8M YoY; R&D expenses $47.5M, G&A $12.7M.","Cash and marketable securities $539.8M at March 31, 2026; raised ~$161.8M in public offering.","Bill Schelman promoted to CMO; David Raben transitions to Senior Executive Advisor; Chris Sarchi appointed CCO.","Plan to initiate randomized study of ficerafusp alfa + pembrolizumab with loading and Q3W maintenance in 1L R/M HPV-negative HNSCC in Q3 2026.","FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim analysis mid-2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111905,"accession_number":"0001628280-26-021868","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicara reports FY2025 net loss $138M; cash $414.8M; raises $161.8M in public offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $37.4M, full year $138.0M vs $21.0M and $68.0M in 2024.","R&D expenses $33.0M Q4, $125.1M full year; G&A $8.1M Q4, $30.5M full year.","Cash & securities $414.8M at Dec 31, 2025; added $161.8M net from Q1 2026 offering; expected runway into H1 2029.","Selected 1500mg weekly ficerafusp alfa for Phase 3; initiated FORTIFI-HN01 trial; interim analysis expected mid-2027.","Developing a loading and every-three-week maintenance dose for potential U.S. approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111904,"accession_number":"0001193125-26-076560","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Bicara raises $161.8M in public offering; reports preliminary cash of $414.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds of ~$161.8M from offering of 7.175M shares at $16.00/sh and 2.2M pre-funded warrants.","Preliminary unaudited cash, cash equivalents and investments as of Dec 31, 2025: ~$414.8M.","Proceeds to support commercial infrastructure for ficerafusp alfa, accelerated development, and manufacturing.","Underwriters exercised option for additional 1,406,250 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111903,"accession_number":"0001628280-26-009808","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicara Phase 1b data: ficerafusp alfa 2000mg Q2W shows 48% ORR, 26% CR in 1L HPV-negative HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["48% confirmed ORR and 26% complete response rate in 27 patients with 1L HPV-negative R/M HNSCC.","77% of responders achieved deep responses (≥80% tumor shrinkage); median time to response 1.6 months.","Safety profile consistent with known profile of ficerafusp alfa plus pembrolizumab; generally well tolerated.","Company plans to develop loading and every-three-week maintenance regimen pending regulatory alignment.","Median PFS, DoR, and OS not yet estimable; data continue to mature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111902,"accession_number":"0001628280-26-001766","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bicara selects 1500 mg ficerafusp alfa dose for Phase 3 pivotal HNSCC study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected 1500 mg QW ficerafusp alfa plus pembrolizumab as optimal dose for Phase 3 FORTIFI-HN01 in 1L HPV-negative R/M HNSCC.","Expects substantial enrollment by end-2026 to enable interim analysis mid-2027 for potential accelerated filing.","Plans to present Phase 1b expansion data in 1L HNSCC (Q1 2026) and long-term follow-up (Q2 2026).","Will explore ficerafusp alfa in other solid tumors; Phase 1b mCRC data expected H2 2026.","Planning critical commercial hires in 2026, including Chief Commercial Officer, to prepare for launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128527,"accession_number":"0002023658-25-000112","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Bicara reports 57% ORR in Phase 1b expansion; deeper responses at 1500mg dose; dose declaration on track for Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["750mg ficerafusp alfa + pembrolizumab showed 57% confirmed ORR (17/30) with 10% complete response.","At 1500mg, median depth of response was 82% vs 63% at 750mg at 24 weeks.","Deep response rate (≥80% shrinkage) was 64% at 1500mg vs 27% at 750mg.","Safety profile consistent with known safety; no new tolerability concerns.","Company on track to declare optimal biologic dose for pivotal FORTIFI-HN01 study in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128526,"accession_number":"0002023658-25-000107","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicara Therapeutics reports Q3 net loss of $36.3M, gets FDA Breakthrough Therapy Designation for ficerafusp alfa","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.","Cash, equivalents, investments $407.6M as of Sept 30, 2025; expected to fund operations into H1 2029.","FDA granted Breakthrough Therapy Designation for ficerafusp alfa + pembrolizumab in 1L HPV-negative R/M HNSCC.","Phase 1b data for 750mg weekly dose of ficerafusp alfa + pembrolizumab expected at ESMO Asia 2025.","Expanded management team: Jenna Cohen (Chief Corp Affairs), Tanya Green (Chief Dev Officer), Bill Schelman (VP)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145326,"accession_number":"0002023658-25-000094","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicara Therapeutics Q2 2025: Cash $436.6M, net loss $27.4M; Phase 1/1b data show 54% ORR in HNSCC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $436.6M as of Jun 30, 2025, expected to fund operations into H1 2029.","Q2 2025 net loss $27.4M vs $17.0M in Q2 2024; R&D expenses $24.8M (up $9M YoY) due to FORTIFI-HN01 trial.","Updated Phase 1/1b data: 54% confirmed ORR, median DOR 21.7 months, median OS 21.3 months in 1L HPV-negative R/M HNSCC.","Additional dose-cohort data (750mg weekly, 2000mg Q2W) expected Q4 2025–Q1 2026; enrollment ongoing in pivotal Phase 2/3.","Pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa + pembrolizumab in 1L R/M HNSCC continues enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163723,"accession_number":"0002023658-25-000082","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bicara Therapeutics shareholders elect three Class I directors, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kiran Mazumdar-Shaw, Jake Simson, and Ryan Cohlhepp as Class I directors for three-year terms.","Vote results: Mazumdar-Shaw 30.8M for, 14.4M withheld; Simson 37.6M for, 7.6M withheld; Cohlhepp 44.8M for, 0.4M withheld.","Broker non-votes of approximately 2.6M shares on each director election.","Ratification of KPMG as auditor for FY2025 passed with 47.7M for, 7.8K against, 3.3K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163722,"accession_number":"0002023658-25-000063","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bicara Therapeutics subleases 9,682 sq ft of HQ office space through June 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease covers approx. 9,682 sq ft at 116 Huntington Ave, Boston, MA.","Base rent: $532,510/yr (Year 1), $543,160.20 (Year 2), $554,023.40 (Year 3).","Sublease term ends June 30, 2027; security deposit of $45,263.35 required.","Effective upon consent of Columbia Reit – 116 Huntington, LLC received June 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163721,"accession_number":"0002023658-25-000034","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicara Therapeutics Q1 net loss $36.8M; cash $462M; ASCO data update planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $462.1M as of March 31, 2025, expected to fund operations into H1 2029.","Net loss of $36.8M in Q1 2025, versus $12.5M in Q1 2024; R&D expenses rose to $34.3M.","Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at ASCO 2025 (June 1).","cSCC monotherapy expansion cohort showed ORR of 30.4% and median PFS of 7.0 months at AACR.","Pivotal Phase 2/3 FORTIFI-HN01 trial enrolling; additional expansion cohorts ongoing or planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181602,"accession_number":"0002023658-25-000006","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.","Cash and equivalents $489.7M as of Dec 31, 2024, up from $230.4M; funds operations into first half 2029.","First patients dosed in February 2025 in FORTIFI-HN01, pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC.","Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting.","Three abstracts on ficerafusp alfa accepted for AACR 2025, including monotherapy in cSCC and preclinical lung cancer data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181601,"accession_number":"0001193125-25-005002","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bicara Therapeutics furnishes corporate presentation, no new material disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation is a general corporate overview; no financial results or guidance provided.","Presentation to be used in investor meetings starting January 13, 2025.","Presentation available on company's IR website at ir.bicara.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198379,"accession_number":"0001193125-24-255166","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bicara Therapeutics Q3 net loss $17.5M; cash $520.8M; pivotal HNSCC trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $520.8M as of Sep 30, 2024, funding operations into H1 2029.","Net loss of $17.5M for Q3 2024 vs $22.8M in Q3 2023 (prior year included $13.3M non-cash charge).","IPO in Sep 2024 raised ~$362M gross from 20.125M shares at $18.00; listed on Nasdaq as BCAX.","Pivotal Phase 2/3 trial FORTIFI-HN01 of ficerafusp alfa in 1L R/M HNSCC expected to start late Q4 2024 or early Q1 2025.","Phase 1/1b data showed 64% ORR, 18% CR, median PFS 9.8 months in frontline HPV-negative R/M HNSCC."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214488,"accession_number":"0001193125-24-219617","cik":2023658,"company_name":"Bicara Therapeutics Inc.","ticker":"BCAX","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bicara Therapeutics files amended charter and bylaws post-IPO, increases authorized shares to 500M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized 500 million shares of common stock and 10 million shares of undesignated preferred stock.","Eliminated stockholder ability to act by written consent and to call special meetings.","Established advance notice procedures for stockholder proposals and director nominations.","Amendments effective immediately prior to completion of IPO, as previously disclosed in S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1392921934.3651528,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}